Stock Analysis
Bio-Techne Corporation (TECH) Stock Analysis
Bio-Techne Corporation (TECH) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Bio-Techne Corporation (TECH) currently has an AIQ Score of 56/100, indicating a neutral setup. Risk is the strongest factor at 89/100. Value is the weakest current factor at 26/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
TECH at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $72.43 |
| AIQ Score | 56/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Buy |
| Market Cap | $11.3B |
| P/E Ratio | 37.21 |
| Forward P/E | — |
| EPS | $0.35 |
| Revenue TTM | $321.19M |
| Dividend Yield | 0.00% |
| Beta | 1.28 |
| Volume | 1.86M |
| 52-week range | $43.20-$72.62 |
| RSI 14 | 51.32 |
| 50-Day SMA | $71.85 |
| 200-Day SMA | $61.00 |
| Analyst Price Target | $64.10 |
| Next Earnings | Nov 4, 2026 |
TECH
OverviewTECH Stock Analysis Summary
Bio-Techne Corporation (TECH) currently has an AIQ Score of 56/100, indicating a neutral setup. Risk resilience is the strongest factor at 89/100. Value is the weakest current factor at 26/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, TECH has AIQ Score of 56/100 with Risk resilience base of 89/100 and fading Value at 26/100. Wait for component alignment before adding exposure.
Risk resilience (89/100) leads while Value (26/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · -0.03% stock move · TECH classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is TECH Bullish or Bearish Right Now?
TECH currently has a neutral overall setup. Risk Resilience is the strongest factor at 89/100, while Value is weakest at 26/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Quality is supportive at 66/100.
- - Momentum is constructive at 62/100.
- - Risk Resilience is supportive at 89/100.
- - Price is +0.81% above its 50-day SMA.
- - Technical consensus has more buy votes than sell votes (27 vs 5).
- - Value is the current constraint at 26/100.
- - Analyst target implies -11.50% downside from the latest quote.
Current Consensus
TECH's Technical Analysis Consensus is currently Buy, with 27 buy, 13 neutral, and 5 sell votes. TECH's 14-day RSI is 51.32, which places the stock in a neutral momentum range. TECH's beta is 1.28, indicating greater market sensitivity than the broad market.
What Changed in TECH?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the TECH Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
TECH Decision Framework
Public evidence layers, setup checks, and risk context for Bio-Techne Corporation.
Bio-Techne Corporation (TECH) Stock Analysis
Bio-Techne Corporation has an AIQ Score of 56/100 in a Neutral regime. Risk is strongest at 89/100. Beta is 1.28, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | TECH is in a Neutral AIQ regime with score 56/100. |
| Signal Conflict | The primary conflict is that risk leads at 89/100 while value lags at 26/100. |
| Factor Evidence | Momentum 62/100 · Value 26/100 · Quality 66/100 · Risk 89/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 89/100.
Momentum is 62/100 and RSI (14) is 51.3.
TECH is in a Neutral regime at 56/100.
Risk factor is 89/100 with beta 1.28 and annual volatility 46.71%.
Current conflict: risk leads at 89/100 while value lags at 26/100.
TECH Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
TECH Fundamentals
TECH valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
TECH Technical Analysis
TECH technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
TECH Stock Catalysts
Track TECH earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
TECH Dividend Analysis
TECH dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
TECH Financial Data
TECH revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
TECH Risk Analysis
TECH volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
TECH Stock News
TECH stock news, market tone, recent headlines, and catalyst context.
TECH vs Life Sciences / Tools / CRO Peers
Current peer cohort: TECH · TMO · TXG · ZTS · A. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| TECH Current stock | 56/100 | 26/100 | 62/100 | 89/100 | 0.82 | 46.71% | Current |
| TMO Thermo Fisher Scientific | 51/100 | 39/100 | 60/100 | 62/100 | 0.77 | 30.64% | TECH vs TMO |
| TXG 10x Genomics | 50/100 | 34/100 | 67/100 | 38/100 | 2.42 | 72.52% | TECH vs TXG |
| ZTS Zoetis | 64/100 | 62/100 | 63/100 | 55/100 | -1.78 | 37.61% | TECH vs ZTS |
| A Agilent Technologies | 56/100 | 37/100 | 61/100 | 63/100 | 0.53 | 32.70% | TECH vs A |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 4, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Sep 5, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching TECH
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for TECH
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
TECH Stock FAQ
What is TECH stock price today?
Bio-Techne Corporation's current stock price is $72.43. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is TECH bullish or bearish right now?
TECH's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is TECH's market cap?
TECH's market cap is $11.3B based on the latest completed market-close snapshot from Sep 4, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is TECH's current P/E ratio?
TECH's current P/E ratio is 37.21 based on the latest completed market-close snapshot from Sep 4, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is TECH's RSI?
TECH's 14-day RSI is 51.32 based on the latest completed market-close snapshot from Sep 4, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is TECH above its 50-day and 200-day moving averages?
TECH is 0.81% from its 50-day SMA and 18.73% from its 200-day SMA based on the latest completed market-close snapshot from Sep 4, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is TECH's next earnings date?
TECH's next earnings date is currently listed as Nov 4, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does TECH pay a dividend?
TECH's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 4, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.